ArticleMarine biotechnology (New York, N.Y.)2025
A Novel Hepcidin Isoform Jd-Hep from the Sin Croaker Johnius dussumieri (Cuvier, 1830): Recombinant Expression and Insights into the Antibacterial Property and Modes of Action.
Article in Marine biotechnology (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepcidin is a cysteine-rich antimicrobial peptide that plays an important role in fish immunity. In the current study, we report a novel isoform of hepcidin (Jd-Hep) from Sin croaker, Johnius dussumieri, with an open reading frame (ORF) of 258 nucleotide bases that encodes 85 amino acids containing a signal peptide (24 amino acids), a prodomain (35 amino acids) and a biologically active mature peptide (26 amino acids). Phylogenetic tree analysis showed that J. dussumieri hepcidin belonged to the HAMP2 cluster of hepcidin. The tissue distribution showed that the expression of hepcidin was highest in the liver in wild-caught J. dussumieri. The mature peptide mJd-Hep was recombinantly expressed in a prokaryotic host, E. coli Rosetta-gami™B (DE3) pLysS cells, and the peptide was isolated and purified. The recombinant peptide, rJd-Hep, exhibited notable antibacterial activity against aquatic pathogens such as Aeromonas hydrophila, Vibrio parahaemolyticus, Vibrio harveyi, Vibrio alginolyticus, Vibrio proteolyticus, and Vibrio fluvialis. The mode of action of the peptide was proven to be membrane-based (pore formation and depolarization). The rJd-Hep was found to be non-hemolytic to hRBCs and non-cytotoxic to the mammalian cell line. The peptide showed 85% growth inhibition of cancer cell line, MCF-7. These findings expand our knowledge of the potential application of hepcidin in aquaculture as a therapeutic agent.
Indexed as
Identifiers
39969620What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.